Oncolytics Biotech Reports Nasdaq Minimum Bid Price Non-Compliance

What Happened On July 20, 2026, Oncolytics Biotech Inc. announced it received a letter from the Nasdaq Listing Qualifications Staff notifying the company that its common stock (ONCY) had closed below the $1.00 per share minimum bid price for 30 consecutive business days and is therefore not in compliance with Nasdaq Listing Rule 5550(a)(2). The notice starts a 180-calendar-day compliance period that runs through January 19, 2027. The company’s shares will continue to trade on the Nasdaq Capital Market while it seeks to regain compliance. The 8-K was filed and signed by CFO Kirk Look on July 24, 2026.

Key Details

• Nasdaq letter dated July 20, 2026; 180-calendar-day compliance period until January 19, 2027.
• Trigger: common stock closed below $1.00 per share for 30 consecutive business days (minimum bid price requirement).
• To regain compliance: closing bid of at least $1.00 for a minimum of 10 consecutive business days (unless Nasdaq extends).
• If not cured, the company may be eligible for an additional 180-day period only if it meets Nasdaq’s market value of publicly held shares and other initial-listing standards (except the minimum bid price); otherwise the stock could be subject to delisting.

Why It Matters This filing signals a listing compliance risk: if Oncolytics cannot raise its share price to meet Nasdaq’s $1.00 minimum for the required period, its shares could be delisted from the Nasdaq Capital Market. Delisting can reduce liquidity, limit access for some institutional investors, and potentially move trading to less visible venues (e.g., OTC). For now, trading continues under ticker ONCY and the company says it will monitor the situation and consider options to regain compliance. Investors should be aware of the January 19, 2027 deadline and monitor share-price developments and company updates.